Strengthen Your Science. Fortify Your Evidence

Most CNS programs fail not because the idea was wrong — but because the evidence package couldn't survive scrutiny. We find those vulnerabilities before investors, partners, or regulators do.

SignalNeuro Partners works with neurotherapeutic companies to identify weaknesses in your scientific foundation, sharpen your data strategy, and pressure-test your program against the specific failure modes that define this field.

Evidence Gap Analysis Identify weaknesses in your scientific foundation and data package before they become deal-killers

Program De-Risking Strategic recommendations to improve your probability of success through better patient selection, trial design, and risk mitigation

Study Design Consultation Optimization for CNS-specific challenges: heterogeneous populations, subjective outcomes, and high placebo rates

Biomarker & Endpoint Strategy Objective molecular endpoints that strengthen your scientific case and reduce reliance on subjective measures

Investor Readiness Evidence-based responses to the scientific questions sophisticated neuroscience investors will ask

Ongoing Scientific Advisory Continuous strategic guidance on research priorities, competitive positioning, and program de-risking

Deliverables

Strategic reports, evidence gap assessments, study protocols, and investor presentations. Timelines range from 2–12 weeks, depending on scope.

For Biotech and Pharmaceutical Companies

Decision-grade scientific due diligence for neurotherapeutics and brain health

What we do